Proprietary AI analyst is now available
- Public Comps
- Xtant Medical
Xtant Medical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Xtant Medical and similar public comparables like Theraclion, Meditera, Meta Biomed, Pulmonx and more.
Xtant Medical Overview
About Xtant Medical
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Founded
2006
HQ

Employees
232
Website
Financials (LTM)
EV
$65M
Valuation Multiples
Start free trialXtant Medical Financials
Xtant Medical reported last 12-month revenue of $120M and EBITDA of $9M.
In the same LTM period, Xtant Medical generated $74M in gross profit, $9M in EBITDA, and had net loss of ($245K).
Revenue (LTM)
Xtant Medical P&L
In the most recent fiscal year, Xtant Medical reported revenue of $134M and EBITDA of $16M.
Xtant Medical is profitable as of last fiscal year, with gross margin of 63%, EBITDA margin of 12%, and net margin of 4%.
Financial data powered by Morningstar, Inc.
Xtant Medical Stock Performance
Xtant Medical has current market cap of $62M, and enterprise value of $65M.
Market Cap Evolution
Xtant Medical's stock price is $0.44.
Xtant Medical share price decreased by 4.8% in the last 30 days, and by 40.5% in the last year.
Xtant Medical has an EPS (earnings per share) of $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $65M | $62M | -2.2% | -4.8% | -21.1% | -40.5% | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXtant Medical Valuation Multiples
Xtant Medical trades at 0.5x EV/Revenue multiple, and 7.1x EV/EBITDA.
EV / Revenue (LTM)
Xtant Medical Financial Valuation Multiples
As of June 11, 2026, Xtant Medical has market cap of $62M and EV of $65M.
Xtant Medical has a P/E ratio of (251.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Xtant Medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Xtant Medical Margins & Growth Rates
Xtant Medical decreased revenue by 24% and EBITDA by 85% in the last fiscal year.
In the most recent fiscal year, Xtant Medical reported gross margin of 63%, EBITDA margin of 12%, and net margin of 4%.
Xtant Medical Margins
Xtant Medical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Xtant Medical Operational KPIs
Xtant Medical's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Xtant Medical's Rule of 40 is (21%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xtant Medical's Rule of X is (57%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Xtant Medical Competitors
Xtant Medical competitors include Theraclion, Meditera, Meta Biomed, Pulmonx, AnteoTech, Myomo, Bactiguard, Osang Healthcare, Spectral AI and Klea.
Most Xtant Medical public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 65.4x | - | (9.2x) | - | |||
| 0.9x | - | 11.8x | - | |||
| 1.0x | - | 4.9x | - | |||
| 0.6x | 0.6x | (1.6x) | (1.7x) | |||
| 87.7x | 94.3x | (16.1x) | (26.4x) | |||
| 1.5x | 1.5x | (5.5x) | (5.9x) | |||
| 3.0x | 3.1x | 15.0x | 18.9x | |||
| 0.8x | - | 8.7x | - | |||
This data is available for Pro users. Sign up to see all Xtant Medical competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Xtant Medical
| When was Xtant Medical founded? | Xtant Medical was founded in 2006. |
| Where is Xtant Medical headquartered? | Xtant Medical is headquartered in United States. |
| How many employees does Xtant Medical have? | As of today, Xtant Medical has over 232 employees. |
| Who is the CEO of Xtant Medical? | Xtant Medical's CEO is Sean E. Browne. |
| Is Xtant Medical publicly listed? | Yes, Xtant Medical is a public company listed on NYSE American. |
| What is the stock symbol of Xtant Medical? | Xtant Medical trades under XTNT ticker. |
| When did Xtant Medical go public? | Xtant Medical went public in 2007. |
| Who are competitors of Xtant Medical? | Xtant Medical main competitors include Theraclion, Meditera, Meta Biomed, Pulmonx, AnteoTech, Myomo, Bactiguard, Osang Healthcare, Spectral AI, Klea. |
| What is the current market cap of Xtant Medical? | Xtant Medical's current market cap is $62M. |
| What is the current revenue of Xtant Medical? | Xtant Medical's last 12 months revenue is $120M. |
| What is the current revenue growth of Xtant Medical? | Xtant Medical revenue growth (NTM/LTM) is (11%). |
| What is the current EV/Revenue multiple of Xtant Medical? | Current revenue multiple of Xtant Medical is 0.5x. |
| What is the current EBITDA of Xtant Medical? | Xtant Medical's last 12 months EBITDA is $9M. |
| What is Xtant Medical's EBITDA margin? | Xtant Medical's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Xtant Medical? | Current EBITDA multiple of Xtant Medical is 7.1x. |
| What is the current FCF of Xtant Medical? | Xtant Medical's last 12 months FCF is $4M. |
| What is Xtant Medical's FCF margin? | Xtant Medical's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Xtant Medical? | Current FCF multiple of Xtant Medical is 17.2x. |
| How many companies Xtant Medical has acquired to date? | Xtant Medical hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Xtant Medical has invested to date? | Xtant Medical hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Xtant Medical
Lists including Xtant Medical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.